학술논문
Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes: ID 011
Document Type
Academic Journal
Author
Source
Oncology Research and Treatment. Feb 01, 2014 37 Supp 1:58-58
Subject
Language
English
ISSN
2296-5270